Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2007

View Archived Issues

IPI-504 overcomes gefitinib resistance in non-small cell lung cancer cell lines

Velcade's significant efficacy advantage prompts early end of phase III clinical trial

FDA grants orphan drug designation to Infinity and MedImmune's IPI-504 for GIST

MicroIslet and Progenitor sign manufacturing agreement for MicroIslet-P

FDA approves five-day, once-daily regimen of Levaquin for cUTI and AP

University of Nottingham develops possible HCV vaccine

Provectus announces results of phase I metastatic melanoma study

Recent patents describe novel agents for psychiatric disorders

CP-3242: a novel metallo-beta-lactamase inhibitor profiled at the ICAAC meeting

Update on EpiCept's MAA for Ceplene in E.U.

Sosei completes phase II proof-of-principle trial of AD-337 for FMS

Novel therapeutic agents for thrombotic disorders reported in recent Trigen patent

Phase I/II clinical program to study Torisel/Velcade combination in multiple myeloma

FDA accepts Samaritan's IND for SP-6300 in Cushing's syndrome

Targeted Genetics reports results of RAC hearing on phase I/II trial of tgAAC94

Perseus and Brigham sign research agreement for cardiovascular risk predictor PTX3

MorphoSys initiates phase I trial of HuCAL gold-derived fully human antibody

Bristol-Myers begins phase II trial of p38 kinase inhibitor BMS-582949 for psoriasis

Aphios and Boston University awarded development grant for APH-M109

Phase I trial expanded after alvespimycin shows activity in metastatic breast cancer

Meta-analysis: Pioglitazone reduces ischemic cardiovascular risk in diabetes patients

mGlu2/3 receptor activation with LY-2140023 improves schizophrenia symptoms

Positive preclinical results of novel RSV fusion inhibitor TMC-353121

Triple beta-lactam combination effective in Gram-negative sepsis models

FDA grants Preos orphan drug status in hypoparathyroidism indication

E.U. grants Novo Nordisk approval for use of NovoRapid in elderly people

Smaller dose Tamiflu approved in Europe; expanded use of FluMist approved in U.S.

EMEA grants Progen's PI-88 orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...